"The companies in the diabetes business stand to make "substantial revenue gains," Standard & Poor's Ratings Services said, with more than 280 million people expected to be diagnosed with diabetes over the next 20 years. The surge in patients will likely boost the global market for diabetes treatment to more than $58 billion in 2018 from $35 billion currently. This will provide a buffer against some industry concerns, such as tighter patenting regulations, rising drug development costs and more restricted use of new drugs in public-health systems.

The condition is seen as a major threat to public health.

Research into how to prevent, treat and possibly even cure both type I and type II diabetes is one of the main areas of pharmaceutical research today, with scores of new treatments in the pipeline."

http://seekingalpha.com/article/910881-eli-lilly-and-the-state-of-the-insulin-battle?source=feed